The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
about
Iron therapy in anaemic adults without chronic kidney diseaseIron deficiency in patients with heart failureIs Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea.Intravenous iron exposure and mortality in patients on hemodialysisExercise-induced changes in iron status and hepcidin response in female runners.The relationship between Type D personality, affective symptoms and hemoglobin levels in chronic heart failureOptimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency.The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysisInfluence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study)Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability.Tricuspid regurgitation: clinical importance and its optimal surgical timing.Management of Iron Deficiency Anemia.Iron status in patients with chronic heart failure.Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status.Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.Comorbidities and characteristics of coronary heart disease patients: their impact on health-related quality of life.Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.Ferric carboxymaltose: a review of its use in iron deficiency.Management of anemia in patients with congestive heart failure.Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?Iron i.v. in heart failure: ready for implementation?Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients.General practitioners' awareness of depressive symptomatology is not associated with quality of life in heart failure patients - cross-sectional results of the observational RECODE-HF Study.High prevalence of iron deficiency in patients with acute decompensated heart failure.Vitamin B12 and folate deficiency in chronic heart failure.[Diagnostic approach to iron deficiency anemia].Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: a before-after study.Anemia and acute coronary syndrome: current perspectives.Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.Iron deficiency in chronic heart failure: case-based practical guidanceIntravenous Irons: From Basic Science to Clinical Practice
P2860
Q24187098-3FC04692-2A6B-47AE-A798-B8BEC648DAB6Q26822876-DC55FF2E-27FC-4402-A0A8-5602CAE103DEQ27012538-856CDF24-A422-4449-82C4-223166BF4777Q34200064-BDD3770D-5B9F-4EE7-AF62-CBAC85EBDDC4Q34455198-4BB0232E-25C2-4B28-9086-B0573D87C62DQ34614664-BACB5B09-AFCE-44CD-835D-77836AA3C4E0Q34614964-54D723FF-4E3F-4D2D-BA9F-B6337384D9A3Q34700903-322E6B89-C6A0-4E74-A0A1-B25A7497483DQ35063802-77C31C1C-5B5B-4DD5-BE0D-50D1554CD498Q35088131-BA1F19D8-E64B-42B1-9A0E-9EE3DE2B753AQ35899914-18B468AC-F075-4D7E-A996-FFCB9CE0E77BQ36475511-BA11203C-88F6-4E08-B557-2E2681D3CFA7Q36725515-AB447FDB-0AE5-48DC-AC32-B45F67119242Q36812538-11FC4CDA-9716-4E9D-B503-A15672DD79CCQ36971596-5EAC7F4A-FEA5-47CE-B912-12E341BE3FDBQ37195233-319446FF-B45F-48EA-97E6-C36E41A79BB6Q37250239-B7CD710C-DC59-4F53-8F51-4BBCAB640B00Q37417267-1B847A4A-DC2B-4A9A-B100-71BC7499CC0BQ38236292-37135143-4582-4DAB-B9C7-68A5FBE2EEF0Q38271890-B6B32E79-AA5E-448F-999B-79353C5DF0E5Q38990298-7D51FAD1-E6D0-4FBC-B1A8-6787C8D748CCQ39409288-6C3FEFFF-F33B-4363-BF31-0F67FF314C96Q43185748-8D8CBEF3-624A-43B9-9971-593BF72189AFQ47141724-0E8F901E-4AB1-4A7A-9886-6122FD4E0996Q47683798-0718723B-42E4-4F82-8455-81024948955AQ47744173-1266B71E-A083-41CE-98C2-76178E458BD9Q48062370-3402F44A-CC1E-4FD7-9630-20D689E12CCAQ48092481-50EA22E4-11F5-4D69-97C2-841BB8C32F70Q53642889-7A946D99-E910-4450-BEC8-6D39BCA2BD6FQ54939969-CEAF477F-F907-482D-A950-498FBFF575F6Q55259995-7FD48779-BF48-44A6-B61F-B491D17D5C4DQ56968591-9C59DB9D-4421-4227-8CA5-04907D74D557Q57167424-17C71612-FEC0-478E-A778-A1FF680922DF
P2860
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The effect of intravenous ferr ...... analysis of the FAIR-HF study.
@ast
The effect of intravenous ferr ...... analysis of the FAIR-HF study.
@en
type
label
The effect of intravenous ferr ...... analysis of the FAIR-HF study.
@ast
The effect of intravenous ferr ...... analysis of the FAIR-HF study.
@en
prefLabel
The effect of intravenous ferr ...... analysis of the FAIR-HF study.
@ast
The effect of intravenous ferr ...... analysis of the FAIR-HF study.
@en
P2093
P2860
P50
P356
P1476
The effect of intravenous ferr ...... analysis of the FAIR-HF study.
@en
P2093
Claudio Mori
Gerasimos S Filippatos
Patrick Johnson
P2860
P356
10.1093/EURHEARTJ/EHR504
P50
P577
2012-01-31T00:00:00Z